CEDAR KNOLLS, N.J.,
Jan. 8, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and
the owner of Fortetropin®, a proprietary bioactive
composition derived from fertilized egg yolk that helps build lean
muscle, announces the presentation of study results that
evaluated the impact of Fortetropin® on canine muscle
loss following surgery, on January 20,
2019 at the North American Veterinary Community
(NAVC) / VMX Conference (https://navc.com/vmx/) in
Orlando, Florida.
Kenneth R. Harkin DVM, DACVIM (SAIM), Professor and Section Head,
College of Veterinary Medicine, Kansas State
University and the principal investigator of the study, will
present the results as part of an oral presentation titled,
"The Impact of Fortetropin® Supplementation
on Dogs Recovering from Tibial-Plateau Leveling Osteotomy (TPLO)
Surgery" at 3:15 PM in the
Discovery Theater at the VMX Conference.
The randomized, double-blind, placebo-controlled study evaluated
the impact of Fortetropin on attenuating muscle atrophy following a
common surgical procedure known as tibial-plateau leveling
osteotomy (TPLO) in 100 dogs at Kansas State University. TPLO
is performed by veterinary surgeons to repair ruptures of the
cranial cruciate ligament (CCL), a canine ligament that is
analogous to the anterior cruciate ligament (ACL) in humans.
In the weeks that follow TPLO surgery, the immobilized operated
limb frequently shows significant muscle loss due to muscle disuse
atrophy. The objective of the study was to determine whether
Fortetropin could reduce this muscle atrophy with respect to a
macronutrient-matched placebo.
Joseph Mannello, CEO, MYOS,
commented, "The results of this Kansas State study are not
only relevant to the company's veterinary business, which was
established in 2018, but are also relevant to MYOS' human
muscle nutrition business, with a particular focus on recovery
and rehabilitation."
The Northern American Veterinary Community (NAVC) Conference
/ VMX is one of the leading veterinary conferences in the
world. The event is expected to attract >17,000 veterinary
professionals from around the world in addition to >700
corporate exhibitors. MYOS Canine Muscle
Formula (a Fortetropin product) will be available
at the conference, and is currently available at
myospet.com.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr®, Yolked®, MYOS
Enteral Nutrition Formula™ and MYOS Canine Muscle
Formula™ products, the success of our research and development,
the results of the clinical evaluation of
Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-upcoming-presentation-of-results-from-a-kansas-state-university-study-evaluating-the-impact-of-fortetropin-on-canine-muscle-loss-after-surgery-at-a-major-veterinary-conference-january-20-2019-300774268.html
SOURCE MYOS RENS Technology